For patients facing antibiotic-resistant infections — one of medicine's most pressing crises — the absence of standardized protocols has been a critical barrier to accessing bacteriophage therapy. A formal, consensus-driven clinical guideline published in Nature Medicine now addresses that gap directly, offering the clearest framework yet for translating phage therapy from experimental compassionate use into routine clinical practice.
The guideline consolidates expert consensus on key decision points in personalized phage therapy: patient selection criteria, phage sourcing and characterization requirements, safety monitoring protocols, and endpoints for evaluating therapeutic response. Rather than addressing a single pathogen, the framework is designed to be broadly applicable across bacterial targets, with particular relevance to multidrug-resistant organisms where conventional antibiotics have failed. The emphasis on personalization — matching specific phage strains to individual patient isolates — reflects the fundamental biological reality that phages are highly host-specific, unlike broad-spectrum antibiotics.
This development represents a potentially inflection-point moment for an ancient therapeutic approach that Western medicine largely abandoned after penicillin's arrival but that Eastern European centers, particularly in Georgia and Poland, never stopped practicing. The field has seen accelerating momentum since the mid-2010s, with high-profile compassionate-use cases generating proof-of-concept evidence. However, the lack of regulatory clarity and standardized methodology has constrained both clinical adoption and trial design. By establishing a consensus baseline, this guideline could enable more rigorous randomized controlled trials — the evidence tier that regulatory agencies require for broad approval. Key limitations remain: consensus guidelines reflect expert opinion, not controlled trial data, and the logistical complexity of producing patient-matched phage preparations at scale remains a genuine implementation challenge. Still, for a field that has operated largely on case reports, this marks a meaningful institutional step forward.